Neurofibromatosis type 1 cost-effectiveness of therapy

Neurofibromatosis type 1 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neurofibromatosis type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neurofibromatosis type 1 cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neurofibromatosis type 1 cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neurofibromatosis type 1 cost-effectiveness of therapy
CDC on Neurofibromatosis type 1 cost-effectiveness of therapy
Neurofibromatosis type 1 cost-effectiveness of therapy in the news
Blogs on Neurofibromatosis type 1 cost-effectiveness of therapy
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Neurofibromatosis type 1 cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: